Karen Smith

Karen Smith is recorded as Board Member at Skye Bioscience, Inc. (SKYE) since January 1, 2024 and Board Member at Context Therapeutics Inc. (CNTX) since January 1, 2024. The newest filing on record that lists Karen Smith as Board Member at Skye Bioscience, Inc. (SKYE) is dated April 16, 2026. The newest filing on record that lists Karen Smith as Board Member at Context Therapeutics Inc. (CNTX) is dated April 28, 2026. The proxy statement of IRulya Therapeutics Inc. reports total compensation of $1,347,920 for Karen Smith in fiscal 2023, including a base salary of $336,458. Disclosed compensation is on record for 2 fiscal years. Context Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Skye Bioscience, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Context Therapeutics Inc. includes Martin Lehr (CEO and Board Member), Andy Pasternak (Chairman and Board Member), Jennifer Minai-Azary (CFO) and 6 others.